Decreased serum Ou/Zn sOD in children with Autism

Nutrition and Metabolic Insights

Volumn 2, Issue , 2009, Pages

  Russo, A J ^a  

^a Pfeiffer Treatment Center   (United States)

Author keywords

autism; Cu Zn SOD; GI disease; super oxide dismutase

Indexed keywords

EID: 85133367330     PISSN: None     EISSN: 11786388     Source Type: Journal    
DOI: 10.4137/NMI.S3733     Document Type: Article

References (89)

1. Muhle R., Trentacoste S.V., Rapin I. The Genetics of Autism. Pediatrics. 2004; 113: e472–86.
2. Lamb J.A., Moore J., Bailey A., Monaco A.P. Autism: recent molecular genetic advances. Hum Mol Genet. 2000; 9: 861–8.
3. Korvatska E., Van de Water J., Anders T.F., Gershwin M.E. Genetic and immunologic considerations in autism. Neurobiol Dis. 2002; 9: 107–25.
4. Keller F., Persico A.M. The neurobiological context of autism. Mol Neurobiol 2003; 28: 1–22.
5. Sung Y.J., Dawson G., Munson J., Estes A., Schellenberg G.D., Wijsman E.M. Genetic investigation of quantitative traits related to autism: use of multi-variate polygenic models with ascertainment adjustment. Am J Hum Genet. 2005; 76: 68–81.
6. London E.A. The environment as an etiologic factor in autism: a new direction for research. Environ Health Perspect. 2000; 108: 401–4.
7. Mutter J., Naumann J., Schneider R., Walach H., Haley B. Mercury and autism: accelerating evidence? Neuro Endocrinol Lett. 2005; 26: 439–46.
8. Wakefield A.J., Montgomery S.M. Autism, viral infection and measles-mumps-rubella-vaccination. Isr Med Assoc J. 1999; 1: 183–7.
9. Fombonne E. Are measles infections or measles immunizations linked to autism? J Autism Dev Disord. 1999; 29: 349–50.
10. Edelson S.B., Cantor D.S. Autism: xenobiotic influences. Toxicol Ind Health. 1998; 14: 799–811.
11. Horvath K., Perman J.A. Autism and gastrointestinal symptoms. Curr Gastroenterol Rep. 2002; 4: 251–8.
12. White J.F. Intestinal pathology in autism. Exp Biol Med. (Maywood).2003; 228: 639–49.
13. Horvath K., Papadimitriou J.C., Rabsztyn A., Drachenberg C., Tildon J.T. Gastrointestinal abnormalities in children with autism. J Pediatr. 1999; 135: 559–63.
14. Wakefield A.J., Anthony A., Murch S.H. et al. Walker-Smith, Entero-colitis in children with developmental disorders. Am J Gastroenterol. 2000; 95: 2285–95.
15. T aylor B., Miller E., Lingam R., Andrews N., Simmons A., Stowe J. Measles, mumps, and rubella vaccination and bowel prob-[26] Stubbs EG, Ash E, Williams CP. Autism and congenital cytomegalovirus. J Autism Dev Disord. 1984; 14: 183–9.
16. Tuchman R., Rapin I. Epilepsy in autism. Lancet Neurol. 2002; 1: 352–8.
17. Krause I., He X.S., Gerswin M.E., Shoenfeld Y. Brief report: immune factors in autism: a critical review. J Autism Dev Disord. 2002; 32: 337–45.
18. Hornig M., Lipkin W.I. Infectious and immune factors in the pathogenesis of neurodevelopmental disorders: epidemiology, hypotheses, and animal models. Ment Retard Dev Disabil Res Rev. 2001; 7: 200–10.
19. Pardo C.D., Vargas D.L., Zimmerman A.W. Immunity, neuroglia and neuroinflammation in autism. Int Rev Psych. 2005; 17: 485–95.
20. Ashwood P., Van de Water J. Is autism an autoimmune disease? Autoimmunity Rev. 2004; 3: 557–62.
21. Comi A.M., Zimmerman A.W., Frye V.H., Law P.A., Peeden J.N. Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism. J Child Neurol. 1999; 14: 388–94.
22. Sweeten T.L., Bowyer S.L., Posey D.J., Halberstadt G.M., McDougle C.J. Increased prevalence of familial autoimmunity in probands with pervasive developmental disorders. Pediatrics. 2003; 112: 420–4.
23. Chess S. Follow-up report on autism in congenital rubella. J Autism Child Schizophr. 1977; 7: 69–81.
24. Chess S., Fernandez P., Korn S. Behavioral consequences of congenital rubella. J Pediatrics. 1978; 93: 699–703.
25. Yamashita Y., Fujimoto C., Nakajima E., Isagai T., Matsuishi T. Possible association between congenital cytomegalovirus infection and autistic disorder. J Autism Dev Disord. 2003; 33: 455–9.
26. Stubbs E.G., Ash E., Williams C.P. Autism and congenital cytomegalovirus. J Autism Dev Disord. 1984; 14: 183–9.
27. DeLong G.R., Bean S.C., Brown F.R. Acquired reversible autistic syndrome in acute encephalopathic illness in children. Arch Neurol. 1981; 38: 191–4.
28. Malmstrom B.G. Enzymology of oxygen. Annu Rev Biochem. 1982; 51: 21.
29. Fridovich I. The biology of oxygen radicals. Science. 1978; 201: 875.
30. Forman H.J., Torres M. Redox signaling in macrophages. Mol Aspects Med. 2001; 22: 189.
31. Chauhan A., Chauhan V., Brown W.T., Cohen I.L. Oxidative stress in autism: Increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferring-the antioxidant proteins. Life Sci. 2004; 75: 2539–49.
32. McGinnis W.R. Oxidative stress in autism. Altern Ther Health Med. 2004; 10: 22–36.
33. Yao J.K., Reddy R.D., van Kammen D.P. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs. 2001; 15: 287–310.
34. Prabakaran S., Swatton J.E., Ryan M.M. et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry. 2004; 9: 684–97.
35. Abdalla D.S.P., Monteiro H.P., Oliveira J.A.C., Bechara E.J. Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients. Clin Chem. 1986; 32: 805–7.
36. Bilici M., Efe H., Koroglu M.A., Uydu H.A., Bekaroglu M., Deger O. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord. 2001; 64: 43–51.
37. Kuloglu M., Atmaca M., Tezcan E., Ustundag B., Bulut S. Antioxidant enzyme and malondialdehyde levels in patients with panic disorder. Neuropsychobi-ology. 2002; 46: 186–9.
38. Kuloglu M., Atmaca M., Tezcan E., Gecici O., Tunckol H., Ustundag B. Anti-oxidant enzyme activities and malondialdehyde levels in patients with obsessive-compulsive disorder. Neuropsychobiology. 2002; 46: 27–32.
39. Yorbik O., Sayal A., Akay C., Akbiyik D.I., Sohmen T. Investigation of anti-oxidant enzymes in children with autistic disorder. Prostaglandins Leukot Essent Fatty Acids. 2002; 67: 341–3.
40. Pasca S.P., Nemes B., Vlase L. et al. High levels of homocysteine and low serum paraoxonase 1 arylesterase activity in children with autism. Life Sci. 2006; 78: 2244–8.
41. James S.J., Cutler P., Melnyk S. et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr. 2004; 80: 1611–7.
42. Faber S., Zinn G.M., Kern JC 2nd, Kingston H.M. The plasma zinc/serum copper ratio as a biomarker in children with autism spectrum disorders. Biomarkers. 2009; 14: 171–80.
43. Walsh W.J., Usman A., Tarpey J. Disordered Metal Metabolism in a Large Autism Population, Proceedings of the Amer Psych Assn; New Research: Abstract NR109. New Orleans, May, 2001.
44. Fischer P.W., Giroux A., L'abbe3â M. Effects of Zinc on Mucosa! Copper Binding and on the Kinetics of Copper Absorption. The Journal of Nutrition. 1981; 25: 462–9.
45. Pandey Nalini, Pathak Girish Chandra, Singh Amit Kumar, Sharma Chandra Prakash Enzymic changes in response to zinc nutrition. Journal of Plant Physiology. 2002; 159: 1151–3.
46. Sajdel-Sulkowska E.M. et al. Oxidative Stress in Autism: Elevated Cerebellar 3-nitrotyrosine Levels. American Journal of Biochemistry and Biotechnology. 2008; 4(2): 73–84.
47. Edelson S.B., Cantor D.S. The neurotoxic etiology of the autistic spectrum disorder: a replicative study. Toxicol Ind Health. 2000; 16: 239–47.
48. Hovatta I., Tennant R.S., Helton R. et al. Glyoxalase 1 and glutathione reductase 1 regulate anxiety in mice. Nature. 2005; 438: 662–6.
49. Junaid M.A., Kowal D., Barua M., Pullarkat P.S., Sklower Brooks S., Pullarkat R.K. Proteomic studies identified a single nucleotide polymorphism in glyoxalase I as autism susceptibility factor. Am J Med Genet. 2004; 131: 11–7.
50. Cohen I.L., Liu X., Schutz C. et al. Association of autism severity with a monoamine oxidase A functional polymorphism. Clin Genet. 2003; 64: 190–7.
51. Thornalley P.J. Glyoxalase I-structure, function and a critical role in the enzymatic defense against glycation. Biochem Soc Trans. 2003; 31: 1343–8.
52. Gupta S., Agarwal S., Heads C. Brief report: dysregulated immune system in children with autism: beneficial effects of intravenous immune globulin on autistic characteristics. J Autism Dev Disord. 1996; 26: 439–52.
53. Ferrari P., Marescot M.R., Moulias R. et al. Immune status in infantile autism. Correlation between the immune system, autistic symptoms and levels of serotonin. Encephale. 1988; 5: 339–44.
54. Vargas D.L., Nascimbene C., Krishnan C., Zimmerman A.W., Pardo C.A. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 2005; 57: 67–81.
55. Ashwood P., Wakefield A.J. Immune activation of peripheral blood and mucosal CD3+ lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms. J Neuroimmunol. 2006; 173: 126–34.
56. Singh V.K., Warren R.P., Odell J.D., Warren W.L., Cole P. Antibodies to myelin basic protein in children with autistic behavior. Brain Behav Immunol. 1993; 7: 97–103.
57. Russo A.J., Krigsman A., Jepson B., Wakefield A. Anti-PR3 and Anti-MPO IgG ANCA in autistic children with chronic GI disease. Immunology and Immunogenetics Insights. 2009; 2: 21–8.
58. Russo A.J., Krigsman A., Jepson B. Wakefield A, Low Serum Alpha-1 Antitrypsin associated with Anti-PR-3 ANCA in autistic children with GI disease, accepted for publication. Genomics Insights. 2009; 2: 1–9.
59. Zoroglu S.S., Armutcu F., Ozen S. et al. Increased oxidative stress and altered activities of erythrocyte free radical scavenging enzymes in autism. Eur Arch Psychiatry Clin Neurosci. 2004; 254: 143–7.
60. Upchurch G.R., Welch G.N., Fabian A.J. et al. Homocyst(e)ine decreases bio-available nitiric oxide by a mechanism involving glutathione peroxidase. JBiol Chem. 1997; 272: 17012–7.
61. Hindley S., Juurlink B.H.J., Gysbers J.W., Middlemiss P.J., Herman M.A.R., Rathbone M.P. Nitric oxide donors enhance neurotrophin-induced neurite outgrowth through a cGMP-dependent mechanism. J Neurosci Res. 1997; 47: 427–39.
62. Truman J.W., De Vente J., Ball E.E. Nitric oxide-sensitive guany-late cyclase activity is associated with the maturational phase of neuronal development in insects. Development. 1996; 122: 3949–58.
63. Wong J.M., Billiar T.R. Regulation and function of inducible nitric oxide synthase during sepsis and acute inflammation. Adv Pharmacol. 1995; 34: 155–70.
64. Nussler A.K., Di Silvio M., Billiar T.R. et al. Stimulation of the nitric oxide synthase pathway in human hepatocytes by cytokines and endotoxin. J Exp Med. 1992; 176: 261–4.
65. Mutter J., Naumann J., Schneider R., Walach H., Haley B. Mercury and autism: accelerating evidence? Neuro Endocrinol Lett. 2005; 26: 439–46.
66. James S.J., Slikker W., Melnyk S., New E., Pogribna M., Jernigan S. Thimero-sal neurotoxicity is associated with glutathione depletion: protection with glutathione precursors. Neurotoxicology. 2005; 26: 1–8.
67. Gutterridge J.M.C., Richmond R., Halliwell B. Oxygen free-radicals and lipid peroxidation. Inhibition by the protein cerulo-plasmin. FEBS Lett. 1980; 112: 269–72.
68. Loeffler D.A., Connor J.R., Juneau P.L. et al. Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J Neurochem. 1995; 65: 710–24.
69. Chauhan A., Chauhan V., Brown W.T., Cohen I.L. Oxidative stress in autism: Increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin—the antioxidant proteins. Life Sci. 2004; 75: 2539–49.
70. McGinnis W.R. Oxidative stress in autism. Altern Ther Health Med. 2004; 10: 22–36.
71. Horrobin D.F. The phospholipid concept of psychiatric disorders to the neu-rodevelopmental concept of schizophrenia. In: Peet M., Glen I., Horrobin D.F., editors. Phospholipid Spectrum Disorder in Psychiatry. Lancashire, UK: Maurius Press; 1999. pp. 3–20.
72. Puri B.K., Richardson A. Brain phospholipid metabolism in dyslexia assessed by magnetic resonance spectroscopy. In: Peet M., Glen I., Horrobin D.F., editors. Phospholipid Spectrum Disorder in Psychiatry. Lancashire, UK: Maurius Press; 1999. pp. 243–50.
73. Lenaz G. The mitochondrial production of reactive oxygen species: mechanisms and implications in human pathology. IUBMBLife. 2001; 52: 159–64.
74. Kowaltowski A.J., Vercesi A.E. Mitochondrial damage induced by conditions of oxidative stress. Free Radic Biol Med. 1999; 26: 463–71.
75. Kroemer G., Dallaporta B., Resch-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol. 1998; 60: 619–42.
76. Fatemi S.H., Halt A.R., Stary J.M., Kanodia R., Schulz S.C., Realmuto G.R. Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices. Biol Psychiatry. 2002; 52: 805–10.
77. Aldred S., Moore K.M., Fitzgerald M., Waring R.H. Plasma amino acid levels in children with autism and their families. J Autism Dev Disord. 2003; 33: 93–7.
78. Uchida K., Shiraishi M., Naito Y., Torii N., Nakamura Y., Osawa T. Activation of stress signalling pathways by the end product of lipid peroxidation. J Biol Chem. 1999; 274: 2234–42.
79. Parola M., Bellomo G., Robino G., Barrera G., Dianzani M.U. 4-hydroxynonenal as a biological signal: molecular basis and pathophysiological implications. Antioxidant Redox Signal. 1999; 1: 255–84.
80. de la Fuente M., Victor V.M. Ascorbic acid and N-acetylcysteine improve in vitro the function of lymphocytes from mice with endotoxin-induced oxidative stress. Free Radic Res. 2001; 35: 73–84.
81. de la Fuente M., Miguel J., Catalan M.P., Victor V.M., Guayerbas N. The amount of thiolic antioxidant ingestion needed to improve several immune functions is higher in aged than in adult mice. Free Radic Res. 2002; 36: 119–26.
82. Viora M., Quarante M.G., Straface E., Vari R., Masella R., Malomi W. Redox imbalance and immune functions: opposite effects of oxidized low-density lipoproteins and N-acetylcysteine. Immunology. 2001; 104: 431–8.
83. McGinnis W.R. Oxidative stress in autism. Altern Ther Health Med. 2004; 10: 22–36.
84. Ashwood P., Wakefield A.J. Immune activation of peripheral blood and mucosal CD3+ lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms. J Neuroimmunol. 2006; 173: 126–34.
85. Chez M.G., Buchanan C.P., Aimonovitch M.C., Becker M., Black C., Komen J. Double-blind, placebo-controlled study of 1-carnosine supplementation in children with autism spectrum disorders. J Child Neurol. 2002; 17: 833–7.
86. Rimland B., Callaway E., Dreyfus P. The effect of high doses of Vitamin B6 on autistic children: a double-blind crossover study. Am J Psychiatry. 1978; 135: 472–5.
87. Kleijnen J., Knipschild P. Niacin and Vitamin B6 in mental functioning: a review of controlled trials in humans. Biol Psychiatry. 1991; 29: 931–41.
88. Zoroglu S.S., Armutcu F., Ozen S. et al. Increased oxidative stress and altered activities of erythrocyte free radical scavenging enzymes in autism. Eur Arch Psychiatry Clin Neurosci. 2004; 254: 143–7. 33.
89. Evans T.A. et al. The Autistic Phenotype Exhibits a Remarkably Localized Modification of Brain Protein by Products of Free Radical-Induced Lipid Oxidation. American Journal of Biotechnology and Biochemistry. 2008; 4(2): 61–72.